One-fifth of late-stage can­cer tri­als changed pri­ma­ry end­points af­ter tri­al start, JA­MA Net­work Open study says

Near­ly 20% of Phase III clin­i­cal tri­als for can­cer ther­a­pies had their pri­ma­ry end­points changed af­ter be­ing pub­licly re­port­ed, ac­cord­ing to a study pub­lished in JA­MA Net­work Open last week.

The pa­per, co-au­thored by re­searchers at the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter and the Bay­lor Col­lege of Med­i­cine, among oth­ers, ex­am­ined late-stage ran­dom­ized can­cer tri­als reg­is­tered on Clin­i­cal­Tri­als.gov. The re­searchers con­clud­ed that the lack of trans­paren­cy among ran­dom­ized tri­als is a “press­ing con­cern.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER